Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Hobart

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
Journal of Neurology|September 30, 2011
Psychometric performance of a generic walking scale (Walk-12G) in multiple sclerosis and Parkinson's diseaseStina Bladh, Maria H Nilsson, Gun-Marie Hariz, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 21, 2012
Putting the Alzheimer's cognitive test to the test II: Rasch Measurement TheoryJeremy Hobart, Stefan Cano, Holly Posner, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 12, 2013
Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosisJeremy Hobart, Stefan Cano, Rachel Baron, et al.
Multiple Sclerosis and Related Disorders|June 16, 2024
Reconciling lesions, relapses and smouldering associated worsening: A unifying model for multiple sclerosis pathogenesisNiraj Mistry, Jeremy Hobart, David Rog, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 5, 2007
Measuring health-related quality of life in MSA: the MSA-QoLAnette Schrag, Caroline Selai, Chris Mathias, et al.
Multiple Sclerosis and Related Disorders|June 16, 2023
Do clinical trials prepare to fail by failing to prepare? An examination of MS trials and recommendations for patient-reported outcome measure selectionJeremy Hobart, Tanuja Chitnis, Jiwon Oh, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial resultsLahar Mehta, Manjit McNeill, Jeremy Hobart, et al.
Therapeutic Advances in Neurological Disorders|May 23, 2022
Efficacy of prolonged-release fampridine <i>versus</i> placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCERaymond Hupperts, Claudio Gasperini, Jan Lycke, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 9, 2013
Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: a new approachHolly B Posner, Stefan Cano, Maria C Carrillo, et al.
The Lancet. Neurology|July 17, 2013
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trialJohn Zajicek, Susan Ball, David Wright, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Journal of Neurology|September 30, 2011
Psychometric performance of a generic walking scale (Walk-12G) in multiple sclerosis and Parkinson's diseaseStina Bladh, Maria H Nilsson, Gun-Marie Hariz, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 21, 2012
Putting the Alzheimer's cognitive test to the test II: Rasch Measurement TheoryJeremy Hobart, Stefan Cano, Holly Posner, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 12, 2013
Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosisJeremy Hobart, Stefan Cano, Rachel Baron, et al.
Multiple Sclerosis and Related Disorders|June 16, 2024
Reconciling lesions, relapses and smouldering associated worsening: A unifying model for multiple sclerosis pathogenesisNiraj Mistry, Jeremy Hobart, David Rog, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 5, 2007
Measuring health-related quality of life in MSA: the MSA-QoLAnette Schrag, Caroline Selai, Chris Mathias, et al.
Multiple Sclerosis and Related Disorders|June 16, 2023
Do clinical trials prepare to fail by failing to prepare? An examination of MS trials and recommendations for patient-reported outcome measure selectionJeremy Hobart, Tanuja Chitnis, Jiwon Oh, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial resultsLahar Mehta, Manjit McNeill, Jeremy Hobart, et al.
Therapeutic Advances in Neurological Disorders|May 23, 2022
Efficacy of prolonged-release fampridine <i>versus</i> placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCERaymond Hupperts, Claudio Gasperini, Jan Lycke, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 9, 2013
Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: a new approachHolly B Posner, Stefan Cano, Maria C Carrillo, et al.
The Lancet. Neurology|July 17, 2013
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trialJohn Zajicek, Susan Ball, David Wright, et al.
Pageof 7